AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

AMD CEO and Chairman Dr. Lisa Su updated the size of the total addressable market for the AI data center and now sees it hitting $1T by 2030, up from a prior view of $500B.

Maverick malware spreads via WhatsApp Web, targeting Brazilian banks through PowerShell and browser hijacking.

The Dark Enlightenment of AI has turned efficiency into ideology. Here’s how it’s reshaping brands, leadership, and the ...

Electroencephalography (EEG) is a fascinating noninvasive technique that measures and records the brain's electrical activity ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

AI agents took center stage at the November MarTech Conference, where leaders unpacked how orchestration, agility and ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed.

In 2026, AI can make very small discoveries but in 2028 and beyond, OpenAI is confident that “we will have systems that can ...